Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
January 09, 2024 08:00 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108
December 28, 2023 08:00 ET
|
Palisade Bio, Inc.
- Company’s co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding as part of previously announced grant from the US Crohn’s and Colitis Foundation - Lead program, PALI-2108 for...
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook
November 10, 2023 08:05 ET
|
Palisade Bio, Inc.
– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral prodrug therapy for the treatment...
Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference
October 11, 2023 09:05 ET
|
Palisade Bio, Inc.
Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq:...
Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules
September 11, 2023 16:01 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is...
Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
September 11, 2023 08:35 ET
|
Palisade Bio, Inc.
Announces Awarding of Inducement Grant to New Chief Medical Officer Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a...
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules
September 07, 2023 08:30 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is...
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
September 06, 2023 08:45 ET
|
Palisade Bio, Inc.
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 – Inflammatory bowel...
Palisade Bio Reports Second Quarter 2023 Financial Results
August 11, 2023 08:05 ET
|
Palisade Bio, Inc.
– Company accelerating late-stage corporate development activities to in-license/acquire synergistic assets to build GI-focused pipeline – Strong financial position with cash to fund...
Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions
August 09, 2023 08:05 ET
|
Palisade Bio, Inc.
– Study did not achieve primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surgery Carlsbad, CA, Aug. 09, 2023 ...